Orum Therapeutics, Inc. (KOSDAQ:475830)

Orum Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	20,881	20,906	135,418	75.92
Revenue Growth (YoY)	-84.57%	-84.56%	178270.49%	-
Cost of Revenue	0.43	1.99	-	0.83
Gross Profit	20,881	20,904	135,418	75.09
Selling, General & Admin	10,157	9,158	19,054	9,083
Research & Development	21,909	17,043	18,706	33,168
Other Operating Expenses	140.56	170.3	280.11	182.18
Operating Expenses	35,570	29,239	39,811	43,723
Operating Income	-14,689	-8,335	95,607	-43,648
Interest Expense	-1,867	-1,794	-824.35	-75.37
Interest & Investment Income	2,023	3,179	560.83	671
Currency Exchange Gain (Loss)	-1,433	-4,609	-5,642	-799.86
Other Non Operating Income (Expenses)	5,668	5,445	-21,199	-19,197
EBT Excluding Unusual Items	-10,299	-6,114	68,502	-63,050
Gain (Loss) on Sale of Investments	1,826	799.27	-809.55	-52.63
Gain (Loss) on Sale of Assets	66.12	-	205.25	8.91
Pretax Income	-8,406	-5,315	67,898	-63,093
Income Tax Expense	425.37	424.98	-319.02	225.34
Net Income	-8,832	-5,740	68,217	-63,319
Net Income to Common	-8,832	-5,740	68,217	-63,319
Shares Outstanding (Basic)	19	14	5	5
Shares Outstanding (Diluted)	19	18	15	5
Shares Change (YoY)	14.29%	20.20%	227.30%	-
EPS (Basic)	-453.17	-423.62	14829.83	-13764.93
EPS (Diluted)	-675.12	-555.93	5646.14	-13764.93
Free Cash Flow	-16,891	-12,545	93,117	-41,888
Free Cash Flow Per Share	-866.72	-693.22	6184.75	-9106.02
Gross Margin	100.00%	99.99%	100.00%	98.91%
Operating Margin	-70.35%	-39.87%	70.60%	-57492.65%
Profit Margin	-42.29%	-27.46%	50.38%	-83402.60%
Free Cash Flow Margin	-80.89%	-60.01%	68.76%	-55173.99%
EBITDA	-11,544	-5,467	97,377	-42,358
EBITDA Margin	-55.28%	-26.15%	71.91%	-
D&A For EBITDA	3,145	2,868	1,771	1,290
EBIT	-14,689	-8,335	95,607	-43,648
EBIT Margin	-70.35%	-39.87%	70.60%	-
Advertising Expenses	-	4.37	3.95	10.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.